- Executive Vice President and Associate Center Director for Translational Research
- Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment
- Co-Director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center.
Dr. Mulé is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors. He has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy; and he has been an NCI-NIH investigator continuously for nearly 20 years.
Dr. Mulé serves on the advisory board of M2Gen, a wholly-owned subsidiary of the Moffitt Cancer Center in the area of personalized medicine in oncology, which he helped to establish; the Board of Directors of Medicine in Need, Cambridge, MA (a non-profit spin-out of Harvard University, and selected as a 2011 Technology Pioneer by the World Economic Forum); and the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A, clinical), remaining a long-standing special government employee to the FDA and the NCI; the scientific/medical advisory boards of several private and public companies where he also served as a consultant; and he chaired the FDA’s CBER Cellular, Tissue, and Gene Therapy Advisory Committee.
I am a Computer Research Scientist in the Environmental Genomics and Systems Biology division at Lawrence Berkeley Laboratory. My work focuses on computational methods for representing and interpreting complex biological data, in particular through the development and application of knowledge representation structures such as ontologies.
Cardiologist, Scripps Clinic; Assistant Professor, Scripps Translational Science Institute; Visiting Scholar, University of California - San Diego. Judge, Qualcomm Tricorder XPRIZE; Fellow of the American College of Cardiology. M.D., PhD. - Albert Einstein College of Medicine; M.C.T.I.- The Scripps Research Institute.
I received my PhD in Reproductive Endocrinology from University of Madras, India where I studied the molecular mechanism underlying the repression of follicle stimulating hormone receptor and androgen receptor in Sertoli cells of F1 progeny rats with gestational exposure to hexavalent chromium. I have successfully attained inter-laboratory collaboration to study the effect of gestational exposure to excess hexavalent chromium on insulin signaling molecules and glucose homeostasis in F1 progeny rats. Currently, my research focus is to understand the role of gonadal macrophage polarization in reproductive dysfunction associated with hypertension in both men and women.
Chief, Division of Infectious Diseases, Children's Hospital of Philadelphia
The primary research goals of our lab are to understand the biological functions of specific metabolic pathways in the malaria parasite--that is, to understand what the parasite needs to make, and why it needs to make it.
Dr. Ogunwobi obtained a medical degree from the University of Ibadan, Nigeria, a master's degree in biomedicine from the University of Hull, United Kingdom, a master's degree in clinical and translational science from the University of Florida, Gainesville, and a PhD in molecular biology from the University of East Anglia, Norwich, United Kingdom. He was the Founding Director of the Hunter College Center for Cancer Health Disparities Research. He is now the Barnett Rosenberg Professor of Biochemistry and Molecular Biology and Chairperson in the Department of Biochemistry and Molecular Biology at Michigan State University. In addition, he will serve as Co-Director of the forthcoming Center for Cancer Health Equity Research (CCHER) at Michigan State University. He is a translational cancer biologist whose work focuses on molecular mechanisms of progression of solid organ cancers with racial disparities, and on approaches to leverage non-coding RNA biology for potential clinical applications in cancer. His work has been funded by the National Institutes of Health, New York State, Carnegie Corporation of New York, and the National Science Foundation, among others. Dr. Ogunwobi was a Founding Contact Principal Investigator of the Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) funded by U54 grants CA221704 and CA221705 from the National Cancer Institute. An author of 74 peer-reviewed journal articles and 3 book chapters, Dr. Ogunwobi has been issued 5 US patents for biotechnology inventions with potential clinical applications in cancer. He is the recipient of the 2022 Hunter College Presidential Award for Excellence in Scholarship or Creative Activity, and selected as a Jefferson Science Fellow by the National Academies of Sciences, Engineering, and Medicine, and as a Fellow of the Academy of Medicine Specialties of Nigeria. He is Co-Founder of UTR Therapeutics, Inc (winner of the 2023 XSeed Award from Deerfield), and NucleoBio, Inc.
Doctor Sonia Oliveira holds a Licenciatura in Biology (pre-Bologna) and a Master in Cellular and Molecular Biology from the University of Aveiro, where she also specialized in medicinal plants, toxicology, murine models, and spermatogenesis. In 2011 she moved to Australia to work in Reproductive Biological Sciences. She later explored the nerve-cancer connection in Cancer, namely in female cancers, and completed her Ph.D. in Human Physiology ( with a significant component in Medical Biochemistry and Neurophysiology) from the University of Newcastle (Australia) in 2018. She then worked with biomimetic systems and nanotechnology in diabetes and stem cells. She explored multiple methods for primary and secondary cell culture, always with a keen interest in histopathology, cell biology, and rare disorders. Participated in >40 event(s). (Co-)Supervised MSc dissertation(s) and final projects for course completion of LSc/BSc. And works mostly in the area(s) of Natural sciences with emphasis on Molecular and Cellular Biology, and Medical and Health Sciences with emphasis on Neurosciences, Cancer, Reproduction, Toxicology, Biotechnology, and Stem cells. Also has collaborations in Microbiology, Biomaterials, and Communication and Information technologies.
Dr. Pierpaolo Pani is a Associate Professor within the Department of Physiology and Pharmacology, SAPIENZA, University of Rome. He received a MSc in Experimental Psychology and PhD in Neurophysiolgy (Behavioral and Integrative) at Sapienza University (Rome), and was a post-doc in KULeuven (Laboratory for Neuro- and Psychophysiology).
Dr. Pani's main topics of investigation include Cognitive control, executive functions, goal-oriented behavior and decision making. These topics include behavioral and psychophysiological investigations in humans; behavioral and neuronal dynamics investigations in mammals; characterization of executive functions control in psychiatric conditions.
Passionate about understanding the mechanisms governing cancer metastasis with a hope of finding new targetable pathways. Have worked on breast cancer stem cells, EMT, prostate cancer stem cells, breast cancer brain metastasis, and blood-brain barriers.
I obtained my PhD from the Institute of Cancer Research in London spent a further 10 years there as a postdoctoral fellow and Staff Scientist. I am currently a Lecturer in Molecular Biology at the University of Stirling in Scotland. My principal research interest is translational oncology, with a focus on epigenetics.
Professor and Chairman of Biochemistry, Facultad de Medicina, Universidad de la República, Uruguay. Discovery Award of the Society for Free Radical Biology and Medicine (SFRBM, 2011), Alexander Von Humboldt Senior Award (2010), National Prize in Science and Technology (2007). Howard Hughes International Research Scholar (2000-2011). Past-President of SFRBM and of the Society for Free Radical Research International. Foreign Associate of the US National Academy of Sciences (2015). Founding Member and current President of the Academia Nacional de Ciencias del Uruguay.
Professor, Department of Neurology, School of Medicine; Pharmacology and Toxicology Graduate Group; Center for Neuroscience; University of California, Davis. Past president, American Society for Experimental NeuroTherapeutics. Academic editor of 9 journals. Co-founder of Epilepsy Currents, the journal of the American Epilepsy Society.
I received a B.A. (biophysics) from Amherst College, and M.D. and Ph.D. (pharmacology) degrees from Yale University. I was a resident, fellow and assistant professor in the Department of Neurology at the Johns Hopkins University School of Medicine. For over 20 years, I was a senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke. My research interests involve ion channel pharmacology and neurological therapeutics, including antiepileptic drugs and other epilepsy treatment approaches.